miRNAs role in bladder cancer pathogenesis and targeted therapy: Signaling pathways interplay - A review
- PMID: 36682282
- DOI: 10.1016/j.prp.2023.154316
miRNAs role in bladder cancer pathogenesis and targeted therapy: Signaling pathways interplay - A review
Abstract
Bladder cancer (BC) is the 11th most popular cancer in females and 4th in males. A lot of efforts have been exerted to improve BC patients' care. Besides, new approaches have been developed to enhance the efficiency of BC diagnosis, prognosis, therapeutics, and monitoring. MicroRNAs (miRNAs, miRs) are small chain nucleic acids that can regulate wide networks of cellular events. They can inhibit or degrade their target protein-encoding genes. The miRNAs are either downregulated or upregulated in BC due to epigenetic alterations or biogenesis machinery abnormalities. In BC, dysregulation of miRNAs is associated with cell cycle arrest, apoptosis, proliferation, metastasis, treatment resistance, and other activities. A variety of miRNAs have been related to tumor kind, stage, or patient survival. Besides, although new approaches for using miRNAs in the diagnosis, prognosis, and treatment of BC have been developed, it still needs further investigations. In the next words, we illustrate the recent advances in the role of miRNAs in BC aspects. They include the role of miRNAs in BC pathogenesis and therapy. Besides, the clinical applications of miRNAs in BC diagnosis, prognosis, and treatment are also discussed.
Keywords: Biogenesis; Bladder cancer (BC); Oncogenic miRNAs; Pathogenesis; Tumor suppressor (TS) miRNAs.
Copyright © 2023 Elsevier GmbH. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
The microRNA expression signature of bladder cancer by deep sequencing: the functional significance of the miR-195/497 cluster.PLoS One. 2014 Feb 10;9(2):e84311. doi: 10.1371/journal.pone.0084311. eCollection 2014. PLoS One. 2014. PMID: 24520312 Free PMC article.
-
miRNAs role in cervical cancer pathogenesis and targeted therapy: Signaling pathways interplay.Pathol Res Pract. 2023 Apr;244:154386. doi: 10.1016/j.prp.2023.154386. Epub 2023 Feb 28. Pathol Res Pract. 2023. PMID: 36868096 Review.
-
MicroRNAs: Key Players in Bladder Cancer.Mol Diagn Ther. 2019 Oct;23(5):579-601. doi: 10.1007/s40291-019-00410-4. Mol Diagn Ther. 2019. PMID: 31325035 Review.
-
Expression profile of microRNAs in bladder cancer and their application as biomarkers.Biomed Pharmacother. 2020 Nov;131:110703. doi: 10.1016/j.biopha.2020.110703. Epub 2020 Sep 2. Biomed Pharmacother. 2020. PMID: 32890965 Review.
-
MicroRNAs and target molecules in bladder cancer.Med Oncol. 2020 Nov 20;37(12):118. doi: 10.1007/s12032-020-01435-0. Med Oncol. 2020. PMID: 33216248 Review.
Cited by
-
Nuclear Receptors in Bladder Cancer: Insights into miRNA-Mediated Regulation and Potential Therapeutic Implications.Int J Mol Sci. 2025 Jul 29;26(15):7340. doi: 10.3390/ijms26157340. Int J Mol Sci. 2025. PMID: 40806474 Free PMC article. Review.
-
Bladder cancer: non-coding RNAs and exosomal non-coding RNAs.Funct Integr Genomics. 2024 Aug 31;24(5):147. doi: 10.1007/s10142-024-01433-9. Funct Integr Genomics. 2024. PMID: 39217254 Review.
-
Deciphering the molecular heterogeneity of intermediate- and (very-)high-risk non-muscle-invasive bladder cancer using multi-layered -omics studies.Front Oncol. 2024 Oct 21;14:1424293. doi: 10.3389/fonc.2024.1424293. eCollection 2024. Front Oncol. 2024. PMID: 39497708 Free PMC article.
-
Exosomal miRNA-based theranostics in cervical cancer: bridging diagnostics and therapy.Med Oncol. 2025 May 4;42(6):193. doi: 10.1007/s12032-025-02752-y. Med Oncol. 2025. PMID: 40320487 Review.
-
Moscatilin Reverses EMT Progression and its Resulting Enhanced Invasion and Migration by Affecting the TGF-β Signaling Pathway in Bladder Cancer.Anticancer Agents Med Chem. 2024;24(14):1074-1084. doi: 10.2174/0118715206307769240522075729. Anticancer Agents Med Chem. 2024. PMID: 38808719
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical